Taysha Gene Therapies (TSHA) Debt to Equity (2020 - 2026)

Taysha Gene Therapies has disclosed Debt to Equity across 7 years of filings, most recently posting $0.23 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.23, down 70.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.23 (down 70.04% YoY), and the FY2025 annual result was $0.2, down 66.97% from the prior year.
• Debt to Equity came in at $0.23 for Q1 2026 at Taysha Gene Therapies, up from $0.2 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $40.01 in Q4 2022 to a low of -$3.65 in Q3 2023.
• The 5-year median for Debt to Equity is $0.48 (2024), against an average of $2.5.
• Across the five-year window, Debt to Equity surged 10160.33% in 2022 and plunged 446.49% in 2023, its largest moves.
• Taysha Gene Therapies' Debt to Equity stood at $40.01 in 2022, then slumped by 98.65% to $0.54 in 2023, then rose by 13.65% to $0.61 in 2024, then plunged by 66.97% to $0.2 in 2025, then grew by 13.85% to $0.23 in 2026.
• The last three Debt to Equity figures came in at $0.23 (Q1 2026), $0.2 (Q4 2025), and $0.23 (Q3 2025), per Business Quant data.